ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6 weeks of the injection 1.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Molecular NeuroImaging
• Collaborator: Institute for Neurodegenerative Disorders
• Treatments: Cocaine

Criteria

Inclusion Criteria:

• The participant is 30 years or older at time of PD diagnosis.

• Written informed consent is obtained.

• Participants have a clinical diagnosis of idiopathic Parkinson's disease of < 7 years.

• Hoehn and Yahr stages I-III.

• Negative drug screen

Exclusion Criteria:

• The participant has atypical or drug-induced Parkinson's disease.

• The participant has dementia.

• The participant has a clinically significant clinical laboratory value and/or clinically significant unstable medical or psychiatric illness.

• Treatment within the six months prior to screening with bupropion, methylphenidate, reserpine, alpha methyldopa, or amphetamine.

• The participant has a history of alcohol, narcotic, or any other drug abuse within the past 2 years.

• The participant has received an investigational drug within 60 days of screening visit.

• Pregnancy